BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 6, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 31, 2017
View Archived Issues
Lilly initiates phase I trial of LY-3200882 in solid tumors
Read More
GlaxoSmithKline begins first-in-human study of GSK-1795091
Read More
Phase II results reported for cabozantinib in patients with carcinoid and pNET
Read More
FDA grants breakthrough therapy designation to uniQure's AMT-060 for hemophilia B
Read More
Roxadustat meets primary endpoints in two phase III anemia trials in China
Read More
Lenvatinib evaluated in patients with RET fusion gene-positive adenocarcinoma of the lung
Read More
EMA accepts peramivir MAA from BioCryst
Read More
Incyte and Calithera Biosciences enter global collaboration to develop and commercialize CB-1158
Read More
Ocera reports topline data from STOP-HE phase IIb study
Read More
Exelixis and Takeda sign exclusive licensing agreement for cabozantinib in Japan
Read More
European Commission approves Votubia to treat refractory partial-onset seizures associated with TSC
Read More
TiGenix initiates phase Ib/IIa trial of Cx-611 to treat sepsis in community-acquired pneumonia
Read More
MJFF awards grants to Addex and Neuropore to support Parkinson's research
Read More
Sebia and Janssen sign agreement for IVD test for multiple myeloma
Read More
Carna Biosciences and EpiBiome establish research collaboration
Read More
Sumitomo Dainippon Pharma recaps highlights of third quarter of fiscal 2016
Read More
Enteris BioPharma licenses oral drug delivery technologies to Ferring
Read More
Preliminary phase I/II results for tosedostat plus capecitabine in metastatic PDAC
Read More
Enanta Pharmaceuticals divulges novel hepatitis B antiviral agents
Read More
Advenchen Laboratories identifies new PI3K/mTOR inhibitors
Read More
Merck & Co. presents novel cholesterol ester transfer protein inhibitors
Read More
AbbVie updates development progress of fourth quarter 2016
Read More
Aurigene Discovery Technologies discovers IRAK-4 inhibitors
Read More
SERPINC1 and FGB gene polymorphisms as prognostic biomarkers in patients with mCRC
Read More